↓ Skip to main content

An in-depth analysis of pharmaceutical regulation in the Republic of Moldova

Overview of attention for article published in Journal of Pharmaceutical Policy and Practice, May 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#41 of 191)
  • High Attention Score compared to outputs of the same age (82nd percentile)

Mentioned by

policy
1 policy source
twitter
5 tweeters

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
An in-depth analysis of pharmaceutical regulation in the Republic of Moldova
Published in
Journal of Pharmaceutical Policy and Practice, May 2014
DOI 10.1186/2052-3211-7-4
Pubmed ID
Authors

Alessandra Ferrario, Nina Sautenkova, Zinaida Bezverhni, Rita Seicas, Jarno Habicht, Panos Kanavos, Vladimir Safta

Abstract

Regulation of the pharmaceutical system is a crucial, yet often neglected, component in ensuring access to safe and effective medicines. The aim of this study was to provide an in-depth analysis of the existing pharmaceutical regulation, including recent changes, in the Republic of Moldova. Data from field work conducted by the World Health Organization (WHO) together with a review of policy documents and quantitative secondary data analysis was used to achieve this aim. This analysis identified several ways in which pharmaceutical regulation affects availability of quality medicines in the Republic of Moldova. These include lack of full implementation bioequivalence requirements for generics registration, incomplete implementation of good manufacturing practices and no implementation of good distribution practices, use of quality control instead of quality assurance as a method to ensure quality of medicines, frequent change of power within the Medicines and Medical Devices Agency (MMDA) leading to lack of long-term strategy and plans, conflict of interest between the different functions of the MMDA, the lack of sufficient funding for the MMDA to conduct its activities and to invest in continuous training of its staff (particularly inspectors) and very weak post-marketing control. Notably, several improvements have been recently introduced, including a roadmap for change for the MMDA, the introduction of good manufacturing practices and the drafting of a quality manual for the Agency. Based on these findings the authors propose a set of priority actions to address existing gaps and draw lessons learned from other countries.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 8%
Unknown 12 92%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 38%
Other 2 15%
Researcher 2 15%
Student > Ph. D. Student 1 8%
Student > Bachelor 1 8%
Other 1 8%
Unknown 1 8%
Readers by discipline Count As %
Nursing and Health Professions 4 31%
Pharmacology, Toxicology and Pharmaceutical Science 4 31%
Business, Management and Accounting 1 8%
Arts and Humanities 1 8%
Decision Sciences 1 8%
Other 1 8%
Unknown 1 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2019.
All research outputs
#2,426,192
of 14,549,400 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#41
of 191 outputs
Outputs of similar age
#32,534
of 188,137 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#1
of 1 outputs
Altmetric has tracked 14,549,400 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 191 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,137 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them